Monoclonal Antibodies Report 2003: Meeting Clinical and Financial Expectations

Published by: Visiongain

Published: Aug. 9, 2003 - 100+ Pages

Table of Contents

• 1.1 Some Facts About Biotechnology
  
• 1.2 The Rise of Biotechnology: A Timeline

2 Monoclonal Antibodies: A Primer

• 2.1 Overview
  
• 2.2 Structure
  
• 2.3 Scientific Preparation
  
• 2.4 Scientific History
  
• 2.5 Mechanism of Action
  
• 2.6 Side Effects
  
• 2.7 Obstacles to Successful Monoclonal Antibody Treatment
  
• 2.8 Types
  
• 2.8.1 Murine
  
• 2.8.2 Chimeric Antibodies
  
• 2.8.3 Humanized Antibodies (CDR-Grafted)
  
• 2.8.4 Human Antibodies

3 Key Products and Therapeutic Applications

• 3.1 Therapeutic Applications
  
• 3.1.1 Transplant Rejection
  
• 3.1.2 Inflammatory Conditions
  
• 3.1.3 Non-Hodgkin's Lymphoma
  
• 3.1.4 Breast Cancer
  
• 3.1.5 Leukemia
  
• 3.1.6 Respiratory Syncytial Virus (RSV)
  
• 3.2 Case Studies
  
• 3.2.1 The Success of Remicade
  
• 3.2.2 Humira: The Future of Monoclonal Antibody Therapy

4 The World Market for Monoclonal Antibodies

• 4.1 Key Product Analysis
  
• 4.1.1 Rituxan
  
• 4.1.2 Zenapax
  
• 4.1.3 Mylotarg
  
• 4.1.4 Synagis
  
• 4.1.5 Herceptin
  
• 4.1.6 Simulect
  
• 4.2 Cost of Monoclonal Antibody Therapy

5 visiongain Analysis: Manufacturing Capacity and Production Demands

• 5.1 Contract Manufacturing
  
• 5.2 Transgenic Protein Production: The New Model to Meet Production Needs
  
• 5.3 Key Players in Contract Manufacturing
  
• 5.3.1 Lonza Biologics
  
• 5.3.2 BioInvent
  
• 5.3.3 Goodwin Biotechnology
  
• 5.4 The Future of Monoclonal Antibody Production
  
• 5.5 Contract Manufacturer Profiles

6 Financial Forecast

• 6.1 Drivers
  
• 6.2 Restraints

7 Research and Development

• 7.1 Humanized vs Human Antibodies
  
• 7.2 Important Products in Clinical Stages
  
• 7.2.1 Erbitux
  
• 7.2.2 ABX-EGF
  
• 7.2.3 Bexxar
  
• 7.2.4 IDEC-151
  
• 7.2.5 Eculizumab
  
• 7.2.6 Pro 542
  
• 7.2.7 Raptiva
  
• 7.2.8 SGN-30
  
• 7.2.9 Xolair
  
• 7.2.10 Therex
  
• 7.2.11 SB249417
  
• 7.2.12 HX8
  
• 7.2.13 MRA
  
• 7.3 Financial Forecast for Select Future Drugs

Appendix


Table I


Glossary

Abstract

Monoclonal Antibodies 2003: Meeting Clinical and Financial Expectations also includes the following information that is vital to those considering entering this growing field:

• Financial state of the monoclonal antibody therapy market and five year forecasts for the market
• Research and development trends and pipeline timelines
• Profiles of the key biotech players in the monoclonal antibody market
• Over 25 graphs and tables
• 100 pages pages full of exclusive in-depth analysis
• The leading monoclonal antibodies report available NOW

In 2002, monoclonal antibody therapy represents approximately 16% of the value of the total global biotechnology industry. This percentage is rising every year and only by reading this unique report will you fully understand what it will be by 2008.

Sales of monoclonal antibodies will reach $5 billion in 2003, an increase of 27% from 2001's figures. But what will they be in 2007 - you should know! This in-depth report will tell you.

Monoclonal Antibodies 2003 assesses the financial state of this burgeoning market and provides vital market share information for the key products in the class. In addition, five year forecasts are provided for the leading antibody therapies on the market as well as for potential blockbusters still in the R&D pipeline.

A special visiongain Analysis chapter delves into the manufacturing capacity issues that are significant growth-limiting factors for this class of drugs. New production models, such as transgenic plants and animals are discussed at length in order to better determine whether production needs can be met in the future. Visiongain also provides an exhaustive list of company profiles for the contract manufacturing industry.

Analysis includes the use of charts and graphs measuring product growth and trends within the monoclonal antibody marketplace. Company-specific information, including sales and revenue figures, licensing arrangements, collaborations, and research and development trends is provided throughout the report.

Please Note: Reports are sold based on the user licenses indicated. The Publisher delivers the report in Flash format via the publisher website, allowing viewing and printing capabilities only. Within one to two business days after placing the order, the Publisher will email the client with information on accessing their purchase. Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

Get Full Details About This Report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.